These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29963237)

  • 1. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
    Hata A; Harada D; Okuda C; Kaji R; Masuda Y; Takechi Y; Kozuki T; Nogami N; Katakami N
    Oncotarget; 2018 Jun; 9(45):27789-27796. PubMed ID: 29963237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).
    Tachihara M; Hata A; Tokito T; Hara S; Okada H; Miura S; Sato Y; Tabata E; Watanabe H; Takayama Y; Toyozawa R; Ota K; Wakuda K; Nakamura A; Shimokawa M; Yamamoto N; Nakagawa K
    JTO Clin Res Rep; 2023 Oct; 4(10):100569. PubMed ID: 37822699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
    Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
    Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
    Mouri A; Kaira K; Shiono A; Yamaguchi O; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):1005-1008. PubMed ID: 30859745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
    Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
    Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
    Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
    Ichihara E; Ochi N; Makimoto G; Kudo K; Harada D; Ozaki Y; Nishio H; Tsuchihashi K; Miura Y; Endo M; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Ito M; Baba E; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Kubo T
    Int J Clin Oncol; 2024 Apr; 29(4):355-362. PubMed ID: 38353907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
    Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
    Zhang JY; Liu YX; Wang H; Mi L; Song GH; Jiang HF; Yan Y; Shao B; Kong WY; Zhang RY; Ran R; Liu XR; Wang J; Lin YT; Li HP
    Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2718-2721. PubMed ID: 30220167
    [No Abstract]   [Full Text] [Related]  

  • 11. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
    Yamamoto A; Iwata T
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1421-1425. PubMed ID: 31530782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measures to Ensure Safety of Docetaxel plus Ramucirumab for Advanced Non-Small-Cell Lung Cancer as the Second- or Later-Line].
    Takase M; Shibata K; Iwasa K; Shimizu M; Fujii Y; Takahashi M
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1039-1042. PubMed ID: 31273171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ; Bai B; Gao YH; Zou DH; Zou SH; Tan H; Song YP; Li ZY; Jin J; Li W; Su H; Gong YP; Zhong MZ; Shuang YR; Zhu J; Zhang JQ; Cai Z; Teng QL; Sun WJ; Yang Y; Xia ZJ; Chen HL; Hua LM; Bao YY; Wu N
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):825-830. PubMed ID: 29166732
    [No Abstract]   [Full Text] [Related]  

  • 17. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
    Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
    Watanabe H; Karayama M; Yasui H; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
    Cancer Treat Res Commun; 2021; 29():100493. PubMed ID: 34844181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.